Statistics Collaborative - Design and analysis for biomedical research

PeoplePeople

Joel Verter, Ph.D.
Senior Vice President

Joel Verter, Ph.D., joined Statistics Collaborative, Inc. (SCI) in 2001. He is a member of the American Statistical Association, the International Biometric Society (Eastern North American Region), and the Society for Clinical Trials (Secretary and Executive Board Member 1995–2003).

From 1967 to 1991, Dr. Verter served as a Commissioned Officer in the United States Public Health Service. During that time, he was assigned to the Biometrics Research Branch of the National Heart, Lung, and Blood Institute (NHLBI), where he served two terms as the acting Branch Chief and contributed to the design, monitoring, and/or analysis of several trials, including the Framingham Heart Study, the Cooperative Study of Sickle Cell Disease (CSSCD), the Aspirin Myocardial Infarction Study (AMIS), the Multiple Risk Factor Intervention Trial (MRFIT), the Studies of Left Ventricular Dysfunction (SOLVD), the Digitalis Investigation Group trial (DIG), the Postmenopausal Estrogen/Progestin Interventions Trial (PEPI), the Bypass Angioplasty Revascularization Investigation (BARI), the Cardiac Arrhythmia Suppression Trial (CAST), the Granulocyte Transfusion trials, and the Penicillin Prophylaxis in Sickle Cell Disease trials (PROPS). During his tenure at the George Washington University Biostatistics Center (1992–2002), he also served as the Principal Investigator of two trials funded by NHLBI: Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) and the Warfarin Antiplatelet Vascular Evaluation (WAVE).

He has served as a member of the Data Monitoring Committees (DMCs) for a number of multi-center clinical trials sponsored by the National Institutes of Health (NIH) and industry. He served a four-year term on the Blood Products Advisory Committee of the Food and Drug Administration (FDA) (1995–1999) and has been a member of several ad hoc FDA Advisory Panels.

His major areas of research are in the fields of clinical trial design, monitoring, and analysis.

He received his B.S. in Mathematics from the City College of New York (1965) and his Ph.D. in Biostatistics from the University of North Carolina at Chapel Hill (1979).